May suppress bone marrow function. Monitor patients for myelosuppression during therapy; not to be given until ANC returns to ≥1,500 cells/mm
3 & platelet count returns to ≥100,000 cells/mm
3. Reduce dose for subsequent cycles based on nadir ANC, platelet count & max non-haematologic toxicity. Possible skin reactions in patients not pre-treated w/ corticosteroid. Consider draining the effusion prior to therapy in patients w/ clinically significant third-space fluid. Possible severe dehydration in combination w/ cisplatin. Possible serious CV events including MI & cerebrovascular events in combination w/ another cytotoxic agent. Possible radiation pneumonitis & recall. Not recommended in concomitant use w/ live attenuated vaccines. Contains Na <1 mmol/vial. May cause fatigue; caution against driving or operating machines if this event occurs. Not recommended in patients w/ CrCl <45 mL/min. Avoid use of NSAIDs in patients w/ mild to moderate renal insufficiency for 2 days before, on the day of, & 2 days following administration. Potential serious renal events including acute renal failure. Women of childbearing potential must use effective contraception during therapy. Advise sexually mature males not to father a child during treatment & up to 6 mth thereafter. Avoid use during pregnancy. Discontinue breastfeeding during therapy. Not recommended for use in childn <18 yr.
Sign Out
